Education/CredentialsMD/PhD: University of CincinnatiBS: University of Alabama Board Certifications & LicensesAmerican Board of Internal Medicine (Certification Date: 2019-08-16)American Osteopathic Board of Internal Medicine (Oncology) (Certification Date: )American Board of Internal Medicine (Medical Oncology) (Certification Date: 2023-11-08) SpecialtiesInternal MedicineMedical Oncology Contact Information Vontz Center Office 513-558-2115 Email leddonjl@ucmail.uc.edu Clinical Interests Lung CancerHematology and OncologyMedical OncologyOncology Abstract Publications Leddon, J.L., Chen, C.Y., Currier, M.A., Wang, P.Y., Jung, F.A., Denton, N.L., Cripe, K.M., Haworth, K.B., Arnold, M.A., Gross, A.C. and Eubank, T.D. 2015. Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity Molecular therapy oncolytics, 1 , 14010Currier, M.A., Eshun, F.K., Sholl, A., Chernoguz, A., Crawford, K., Divanovic, S., Boon, L., Goins, W.F., Frischer, J.S., Collins, M.H. and Leddon, J.L. 2013. VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells Molecular Therapy, 21(5) , 1014Browne, A.W., Leddon, J.L., Currier, M.A., Williams, J.P., Frischer, J.S., Collins, M.H., Ahn, C.H. and Cripe, T.P. 2011. Cancer screening by systemic administration of a gene delivery vector encoding tumor-selective secretable biomarker expression PloS one, 6(5) , 19530
Abstract Publications Leddon, J.L., Chen, C.Y., Currier, M.A., Wang, P.Y., Jung, F.A., Denton, N.L., Cripe, K.M., Haworth, K.B., Arnold, M.A., Gross, A.C. and Eubank, T.D. 2015. Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity Molecular therapy oncolytics, 1 , 14010Currier, M.A., Eshun, F.K., Sholl, A., Chernoguz, A., Crawford, K., Divanovic, S., Boon, L., Goins, W.F., Frischer, J.S., Collins, M.H. and Leddon, J.L. 2013. VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells Molecular Therapy, 21(5) , 1014Browne, A.W., Leddon, J.L., Currier, M.A., Williams, J.P., Frischer, J.S., Collins, M.H., Ahn, C.H. and Cripe, T.P. 2011. Cancer screening by systemic administration of a gene delivery vector encoding tumor-selective secretable biomarker expression PloS one, 6(5) , 19530
Leddon, J.L., Chen, C.Y., Currier, M.A., Wang, P.Y., Jung, F.A., Denton, N.L., Cripe, K.M., Haworth, K.B., Arnold, M.A., Gross, A.C. and Eubank, T.D. 2015. Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity Molecular therapy oncolytics, 1 , 14010Currier, M.A., Eshun, F.K., Sholl, A., Chernoguz, A., Crawford, K., Divanovic, S., Boon, L., Goins, W.F., Frischer, J.S., Collins, M.H. and Leddon, J.L. 2013. VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells Molecular Therapy, 21(5) , 1014Browne, A.W., Leddon, J.L., Currier, M.A., Williams, J.P., Frischer, J.S., Collins, M.H., Ahn, C.H. and Cripe, T.P. 2011. Cancer screening by systemic administration of a gene delivery vector encoding tumor-selective secretable biomarker expression PloS one, 6(5) , 19530